(Page 2 of 2)
CASH ON THE BARRELHEAD
—Life science investors Sofinnova of Menlo Park, CA, announced a new $650 million fund, its tenth. Sunil Agarwal, a veteran of Ultragenyx and Genentech, will join as a partner.
—CRISPR Therapeutics (NASDAQ: CRSP) reeled in $56 million with its IPO, about half what other CRISPR companies’ IPOs earlier this year. It also sold $35 million more in stock to partner Bayer. J-Lo is not a significant shareholder, according to public records.
—South San Francisco’s BlackThorn Therapeutics announced a $40 million Series A round and four drug programs to treat neurobehavioral diseases. One of its drugs should enter Phase 2 studies for depression and other conditions in 2017.
—True North Therapeutics of South San Francisco bagged $45 million in a Series D round to push into later-stage studies with its lead drug to treat a rare form of anemia.
—Boston-based Veritas Genetics, a genetic screening startup co-founded by Harvard University professor George Church, raised a $30 million Series B round and hired three new executives.
—Eli Lilly is committing $90 million to treat disease in the developing world, and $15 million of it will go to Seattle’s Infectious Disease Research Institute.
—This week Xconomy announced New York Life Sciences 2021, a Dec. 15 event in which we’ll look five years into New York’s biotech future.
Ben Fidler contributed to this report.
Photo of Jennifer Lopez courtesy of Steve Bott via Creative Commons.